2013 Press releases
Changes to the Board of Directors
announces that the Chairman, Anders P. Wiklund, and the board members Annette Clancy and Hilde H. Steineger, have decided to resign from the Board of Directors of Clavis Pharma ASA.
CEO Olav Hellebø to leave Clavis Pharma
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces that Olav Hellebø will leave the position as CEO of the company effective 20 May by mutual agreement.
Minutes from Extraordinary General Meeting
The Extraordinary General Meeting elected Martin Nes and Øystein Stray Spetalen as new directors.
Clavis Pharma - First Quarter Results 2013
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces its results for the first quarter 2013, and including significant post-period events.
Recommendation by the Election Committee
Proposal for the extraordinary shareholders meeting May 2nd 2013
Registration to attend the Extraordinary General Meeting on 2 May 2013
Please follow the link below to VPS for electronical registration to attend the Extraordinary General Meeting on 2 May 2013 at 13:00 hours at Parkveien 53B, Oslo.
Clavis Pharma announces negative outcome of Phase III CLAVELA trial with elacytarabine in patients with acute myeloid leukaemia
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces results of the Phase III CLAVELA study investigating elacytarabine ...
Clavis Pharma - Fourth Quarter Results 2012
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces its results for the fourth quarter 2012. A presentation to investors, analysts and the press will take place ..
Invitation to presentation and webcast of Clavis Pharma's fourth quarter results 2012
Clavis Pharma ASA (OSE: CLAVIS) presents the company's fourth quarter 2012 results on Friday 15 February 2013 at Hotel Continental, Stortingsgaten 24/26, Oslo, Norway.
